Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of intravenous anifrolumab in adults with active systemic lupus erythematosus
MOH_2017-02-26_000169Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of anifrolumab in systemic lupus erythematosus (SLE) (3 arms), sponsored by AstraZeneca. Primary endpoint: Not reported. Started Aug 2015; status: active, not recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2017-02-26_000169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-02-26_000169.